CorMedix (CRMD) Misses Q4 EPS by 7c

CorMedix (NASDAQ: CRMD) reported Q4 EPS of ($0.26), $0.07 worse than the analyst estimate of ($0.19).

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight